Smokers using the prescription drug Chantix (varenicline) to help them through the quitting process may want to sip their beers slowly, as this week the FDA approved new warnings that the drug can change the way users react to alcohol. [More]
Our sister publication Consumer Reports Health has posted a new video in their AdWatch series, which examines direct-to-consumer pharmaceutical advertising. This time they’re examining some “stealth” advertising for the quit-smoking drug Chantix.
NY Magazine has published a interesting personal account from a patient who was taking the smoking-cessation drug Chantix. The FDA has reported 37 suicides and more than 400 reports of suicidal behavior in connection with Chantix, a pleasure blocking drug that sits in the nicotine receptors and prevents the smoker from properly experiencing their nicotine high. The FDA recently issued a patient advisory about the drug, requesting that patients carefully monitor their moods. The possible side-effects of Chantix now include “anxiety, nervousness, tension, depressed mood, unusual behaviors and thinking about or attempting suicide.”